Jason J. Luke

Clinical Cancer Research Senior Editor

Dr. Jason J. Luke recently joined the editorial board of Clinical Cancer Research as a Senior Editor. He is an Associate Professor of Medicine and Director of the Cancer Immunotherapeutics Center at the University of Pittsburgh Medical Center’s Hillman Cancer Center. Dr. Luke specializes in both the management of patients with melanoma and early phase drug development.

As a lead national investigator on a number of clinical trials of immunotherapy agents, Dr. Luke’s major translational research is focused on using large scale informatics to advance the field of cancer immunotherapy. He received his medical doctorate from Rosalind Franklin University of Medicine and Science in Chicago, and afterwards pursued internship and residency at the Boston University Medical Center and fellowships at Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center.

In addition to his editorial work for Clinical Cancer Research, Dr. Luke has been an active member of the AACR since 2012. Dr. Luke was the chairperson of a minisymposium entitled “Hitting the Target Harder: Preclinical Development of Potent and Selective Inhibitors” in 2016 and has presented his work at various AACR conferences, with his most recent presentation on the topic of molecular correlates of the non-T cell-inflamed tumor microenvironment at the 2019 AACR-AHNS Head and Neck Cancer Conference in Austin, Texas.

In 2018, Dr. Luke received the Humanitarian Award from the Melanoma Research Foundation and the NCI Cancer Clinical Investigator Team Leadership Award.

Recent AACR Publications:

• Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201)
  Luke JJ…Schwartz GK. Clinical Cancer Research 2019 [Epub ahead of print].
• WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
  Luke JJ…Gajewski TF. Clinical Cancer Research May 2019.
• Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
  Labadie B…Luke JJ. Clinical Cancer Research October 2018.
• T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
  Trujillo JA…Luke JJ. Cancer Immunology Research September 2018.